These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

21 related articles for article (PubMed ID: 7775134)

  • 1. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer.
    Danson S; Ferry D; Alakhov V; Margison J; Kerr D; Jowle D; Brampton M; Halbert G; Ranson M
    Br J Cancer; 2004 Jun; 90(11):2085-91. PubMed ID: 15150584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer.
    Gibbs DD; Pyle L; Allen M; Vaughan M; Webb A; Johnston SR; Gore ME
    Br J Cancer; 2002 May; 86(9):1379-84. PubMed ID: 11986767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma.
    Law TM; Mencel P; Motzer RJ
    Invest New Drugs; 1994; 12(4):323-5. PubMed ID: 7775134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of topotecan in patients with advanced renal cell carcinoma.
    Law TM; Ilson DH; Motzer RJ
    Invest New Drugs; 1994; 12(2):143-5. PubMed ID: 7860232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in renal cell cancer.
    Skubitz KM
    Invest New Drugs; 2002 Feb; 20(1):101-4. PubMed ID: 12003184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altretamine for the treatment of metastatic renal cell carcinoma. A Hoosier Oncology Group trial.
    Zon RT; McClean J; Helman D; Ansari R; Picus J; Sandler A; Williams SD; Loehrer PJ
    Invest New Drugs; 2001; 19(3):229-31. PubMed ID: 11561679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II evaluation of 4'deoxydoxorubicin in advanced renal cell carcinoma.
    Kish JA; Ensley JF; al-Sarraf M
    Am J Clin Oncol; 1990 Feb; 13(1):17-8. PubMed ID: 2305717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reporting results of cancer treatment.
    Miller AB; Hoogstraten B; Staquet M; Winkler A
    Cancer; 1981 Jan; 47(1):207-14. PubMed ID: 7459811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene.
    Fojo AT; Shen DW; Mickley LA; Pastan I; Gottesman MM
    J Clin Oncol; 1987 Dec; 5(12):1922-7. PubMed ID: 3681376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin.
    Rahman A; Treat J; Roh JK; Potkul LA; Alvord WG; Forst D; Woolley PV
    J Clin Oncol; 1990 Jun; 8(6):1093-100. PubMed ID: 2348224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study.
    Treat J; Greenspan A; Forst D; Sanchez JA; Ferrans VJ; Potkul LA; Woolley PV; Rahman A
    J Natl Cancer Inst; 1990 Nov; 82(21):1706-10. PubMed ID: 2231759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes.
    Oudard S; Thierry A; Jorgensen TJ; Rahman A
    Cancer Chemother Pharmacol; 1991; 28(4):259-65. PubMed ID: 1678995
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.